QBFM
NBIX icon

QS Batterymarch Financial Management’s Neurocrine Biosciences NBIX Stock Holding History

QS Batterymarch Financial Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$2.17M Sell
138,391
-13,030
-9% -$195K 0.06% 399
2014
Q2 		$2.25M Sell
151,421
-20,500
-12% -$289K 0.06% 413
2014
Q1 		$2.77M Sell
171,921
-99,630
-37% -$1.7M 0.06% 428
2013
Q4 		$2.54M Sell
271,551
-2,140
-0.8% -$20.9K 0.05% 437
2013
Q3 		$3.1M Buy
+273,691
New +$3.76M 0.07% 405

Other funds holding NBIX

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

QS Batterymarch Financial Management's NBIX Position: Q3 2014 in Review

QS Batterymarch Financial Management reduced its Neurocrine Biosciences (NBIX) stake by 8.6% in Q3 2014, selling an estimated $195K and leaving 138,391 shares worth $2.17M. The position accounts for 0.06% of the portfolio, ranked #399.

QS Batterymarch Financial Management first reported a position in NBIX in Q3 2013 and has held it in 5 quarters since. The position peaked at $3.1M in Q3 2013. 133 funds tracked by Wall St. Rank hold NBIX as of Q3 2014.

  • QS Batterymarch Financial Management held 138,391 shares of Neurocrine Biosciences worth $2.17M as of Q3 2014.
  • QS Batterymarch Financial Management sold 13,030 Neurocrine Biosciences shares in Q3 2014, an estimated $195K.
  • Neurocrine Biosciences made up 0.06% of QS Batterymarch Financial Management's portfolio in Q3 2014, its #399 holding.
  • QS Batterymarch Financial Management first reported a position in Neurocrine Biosciences in Q3 2013 and has held it in 5 quarters since.
  • QS Batterymarch Financial Management's Neurocrine Biosciences position peaked at $3.1M in Q3 2013.
  • 133 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2014.

Based on QS Batterymarch Financial Management's 13F filing for Q3 2014, filed 14 Nov 2014.